BridgeBio Oncology Therapeutics Inc. (BBOT) vs Fulcrum Therapeutics, Inc. (FULC)
A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and Fulcrum Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.60HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
FULC
Fulcrum Therapeutics, Inc.
$3.71HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — BBOT vs FULC
growth of $100 · dividends reinvested · last 3yBBOT -64.7% (-29.3%/yr)FULC -54.5% (-23.1%/yr)FULC compounded faster over this window
BBOT FULC
BBOT vs FULC: by the numbers
- •BBOT is the larger company ($288M vs $283M market cap).
Metrics side by side
Valuation
| Metric | BBOT | FULC |
|---|---|---|
| P/B ratio | 0.89 | 0.91 |
Profitability
| Metric | BBOT | FULC |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -56.36% | -27.36% |
| ROIC | -61.10% | -27.62% |
Growth (annualized)
| Metric | BBOT | FULC |
|---|---|---|
| Total return CAGR (5Y) | N/A | -31.70% |
Go deeper
Dig into the metrics
BridgeBio Oncology Therapeutics ROEFulcrum Therapeutics ROEBridgeBio Oncology Therapeutics operating marginFulcrum Therapeutics operating marginBridgeBio Oncology Therapeutics revenue growthFulcrum Therapeutics revenue growthBridgeBio Oncology Therapeutics free cash flowFulcrum Therapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.